Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXB95R)

Drug Name

IC261 Drug Info

Synonyms

IC-261; IC 261

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Casein kinase I alpha (CSNK1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[3]
US9096594, 3	DM8UOKE	N. A.	N. A.	Patented	[4]
D-4476	DMHD3R8	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[5]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Drug(s) Targeting Casein kinase I delta (CSNK1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
D-4476	DMHD3R8	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[7]
PF-4800567	DM8P9ST	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[8]
PF-670462	DMTJBP9	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[9]
PMID24900428C14	DMU4BL2	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Drug(s) Targeting Casein kinase I epsilon (CSNK1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[10]
PF-4800567	DM8P9ST	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[8]
PF-670462	DMTJBP9	Chronic lymphocytic leukaemia	2A82.0	Preclinical	[9]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Casein kinase I alpha (CSNK1A1)	TTFQEMX	KC1A_HUMAN	Inhibitor	[2]
Casein kinase I delta (CSNK1D)	TTH30UI	KC1D_HUMAN	Inhibitor	[2]
Casein kinase I epsilon (CSNK1E)	TTA8PLI	KC1E_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2	Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60.
3	Clinical pipeline report, company report or official report of BioTheryX.
4	Kinase inhibitors and methods of use thereof. US9096594.
5	Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8.
6	Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64.
7	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
8	Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9.
9	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218.
10	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021